Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018167162 - THERAPEUTIC DOSAGE AND REGIMEN FOR MELATONIN

Publication Number WO/2018/167162
Publication Date 20.09.2018
International Application No. PCT/EP2018/056423
International Filing Date 14.03.2018
IPC
A61K 31/4045 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A61K 9/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
A61P 43/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
CPC
A61K 31/4045
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A61K 47/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
02Inorganic compounds
A61K 47/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
40Cyclodextrins; Derivatives thereof
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • CHIESI FARMACEUTICI S.P.A. [IT]/[IT]
Inventors
  • FACCHINETTI, Fabrizio
  • AQUINO, Giancarlo
  • ROBERTSON, Nicola Jayne
Agents
  • MINOJA, Fabrizio
Priority Data
17161472.017.03.2017EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC DOSAGE AND REGIMEN FOR MELATONIN
(FR) DOSAGE ET RÉGIME THÉRAPEUTIQUES POUR LA MÉLATONINE
Abstract
(EN) The invention relates to a therapeutic regimen for the parenteral administration of melatonin-based formulations to neonates affected by a brain injury disease due to birth asphyxia.
(FR) L'invention concerne un régime thérapeutique pour l'administration parentérale de formulations à base de mélatonine à des nouveau-nés affectés par une maladie par lésion cérébrale due à une asphyxie à la naissance.
Related patent documents
Latest bibliographic data on file with the International Bureau